C4 Therapeutics (NASDAQ:CCCC) Downgraded by Wall Street Zen to “Sell”

Posted by Geri Gentry on Nov 8th, 2026

Wall Street Zen downgraded shares of C4 Therapeutics (NASDAQ:CCCC – Free Report) from a hold rating to a sell rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.

Several other research analysts have also issued reports on the company. Guggenheim started coverage on C4 Therapeutics in a research report on Friday. They set a “buy” rating and a $6.00 target price for the company. Evercore downgraded C4 Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of C4 Therapeutics in a report on Thursday, October 15th. Lake Street Capital started coverage on C4 Therapeutics in a research note on Wednesday, October 28th. They set a “buy” rating and a $11.00 price target for the company. Finally, JPMorgan Chase & Co. initiated coverage on C4 Therapeutics in a report on Friday, October 9th. They set an “overweight” rating and a $10.00 price objective for the company. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

Get Our Latest Stock Analysis on CCCC

C4 Therapeutics Trading Up 5.1%

CCCC stock opened at $3.10 on Friday. The stock has a market cap of $381.39 million, a PE ratio of -4.31 and a beta of 3.16. C4 Therapeutics has a 12 month low of $1.69 and a 12 month high of $5.17. The company has a 50-day moving average price of $3.22 and a 200 day moving average price of $3.22.

C4 Therapeutics (NASDAQ:CCCC – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.03. C4 Therapeutics had a negative net margin of 282.22% and a negative return on equity of 37.03%. The company had revenue of $8.47 million for the quarter, compared to analyst estimates of $8.52 million. Sell-side analysts forecast that C4 Therapeutics will post -0.81 EPS for the current year.

Institutional Investors Weigh In On C4 Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Candriam S.C.A. increased its stake in C4 Therapeutics by 53.6% during the 3rd quarter. Candriam S.C.A. now owns 2,760,346 shares of the company’s stock valued at $9,226,000 after purchasing an additional 963,409 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of C4 Therapeutics by 53.6% during the first quarter. Renaissance Technologies LLC now owns 2,461,815 shares of the company’s stock worth $6,475,000 after buying an additional 859,235 shares during the period. Velan Capital Investment Management LP acquired a new stake in shares of C4 Therapeutics during the second quarter worth $2,662,000. Wasatch Advisors LP grew its holdings in shares of C4 Therapeutics by 18.9% during the second quarter. Wasatch Advisors LP now owns 3,522,644 shares of the company’s stock valued at $16,451,000 after buying an additional 560,883 shares during the last quarter. Finally, Stempoint Capital LP purchased a new stake in shares of C4 Therapeutics during the first quarter valued at $1,192,000. Institutional investors own 78.81% of the company’s stock.

About C4 Therapeutics

(Get Free Report)

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses its proprietary TORPEDO platform to design targeted protein degraders, which are intended to direct specific proteins to the cell’s natural disposal system rather than simply blocking their activity.

C4 Therapeutics has concentrated its research and development efforts primarily on oncology, including programs aimed at genetically defined cancers and difficult-to-treat tumors.